Medical Supply Chain Resiliency Act

Senate Bill

S. 998

119th Congress

Medical Supply Chain Resiliency Act

In Committee

Introduced:Mar 12, 2025

Primary Sponsor

Thomas Tillis

Senator

Republican

NC

Cosponsors

3

Quick Stats

Policy Area

Foreign Trade and International Finance

Summary

This bill allows the President to negotiate special trade agreements with trusted partners to reduce tariffs and barriers on medical supplies, drugs, and pharmaceutical ingredients to strengthen supply chains.

Latest Action

Read twice and referred to the Committee on Finance.

SponsorThomas Tillis (R-NC)

Introduced3/12/2025

StatusRead twice and referred to the Committee on Finance.

ChamberSenate

Data from Congress.gov

See this page through your district lens

Enter ZIP to personalize representatives and vote context.

Stay on top of this issue

Subscribe for weekly bill and representative updates.

Vote Prediction

Medical Supply Chain Resiliency Act

This bill allows the President to negotiate special trade agreements with trusted partners to reduce tariffs and barriers on medical supplies, drugs, and pharmaceutical ingredients to strengthen supply chains.

Community Breakdown

Pass

0%

Fail

0%

0 predictions

This bill allows the President to negotiate special trade agreements with trusted partners to reduce tariffs and barriers on medical supplies, drugs, and pharmaceutical ingredients to strengthen supply chains.

Bill Number: 998
Sponsor: Thomas Tillis (R-NC)
Introduced: 3/12/2025
Status: Read twice and referred to the Committee on Finance.
Policy Area: Foreign Trade and International Finance

Data from Congress.gov

AI-generated summary

Fact Sheet

Title: Medical Supply Chain Resiliency Act
Bill Number: 998
Sponsor: Thomas Tillis (R-NC)
Status: Read twice and referred to the Committee on Finance.
Introduced: 3/12/2025
Summary: This bill allows the President to negotiate special trade agreements with trusted partners to reduce tariffs and barriers on medical supplies, drugs, and pharmaceutical ingredients to strengthen supply chains.

Data from Congress.gov

AI Summary

Plain-English explanation of this bill

This bill allows the President to negotiate special trade agreements with trusted partners to reduce tariffs and barriers on medical supplies, drugs, and pharmaceutical ingredients to strengthen supply chains.

Last updated: 12/30/2025

Official Summary

Congressional Research Service summary

Medical Supply Chain Resiliency ActThis bill authorizes actions to facilitate trade in medical goods (i.e., medical devices, pharmaceutical goods, or inputs for such devices or goods).Specifically, the bill authorizes the President to (1) negotiate, enter into, and enforce a trusted trade partner agreement with a country or countries with respect to medical goods; and (2) proclaim a modification of any existing duty, a continuance of existing duty-free or excise treatment, or additional duties to carry out the trade agreement. These actions may only be taken if the President determines, based on specified considerations, that the reciprocal elimination of existing duties or other import restrictions with respect to medical goods would contribute to U.S. national security and public health. A trusted trade partner agreement may include certain provisions, such as those to (1) reduce or eliminate duties, quotas, or other trade barriers; (2) diversify and expand supplier networks to secure a reliable supply of medical goods; and (3) harmonize regulatory procedures.Not later than 60 days before initiating negotiations with a trusted trade partner, the President must submit written notice to Congress. The bill requires congressional consultation and review of these trade agreements. A trade agreement shall not take effect if, during the required review period, Congress enacts a joint resolution of disapproval.The Office of the U.S. Trade Representative must monitor compliance by a trusted trade partner with the trade agreement's commitments and obligations. Further, the President may take certain actions in response to a failure to comply.

Key Points

Main provisions of the bill

Authorizes trusted trade partner agreements for medical goods
Can reduce or eliminate duties on pharmaceuticals and devices
Requires Congressional review before taking effect
Aims to diversify and secure medical supply chains

How This Impacts Americans

Potential effects on citizens and communities

Hospitals, pharmacies, and patients could benefit from more reliable supplies of medications and medical devices if trade agreements diversify supply sources beyond China. Drug and device prices could also be affected.

Policy Areas

Primary Policy Area

Foreign Trade and International Finance

Scope & Jurisdiction

Jurisdiction Level

federal

Congressional Session

119th Congress

Citation Reference

998, 119th Congress (2025). "Medical Supply Chain Resiliency Act". Source: Voter's Right Platform. https://votersright.org/bills/118-s-998

Public Opinions

Community submissions related to this bill.

Share your opinion

No public opinions yet. Be the first to submit one for this bill.

Related Bills in Foreign Trade and International Finance

HR 1903

Congressional Trade Authority Act of 2025

Referred to the Committee on Ways and Means, and in addition to the Committee on Rules, for a period

HR 4044

Foundation for America’s Public Lands Reauthorization Act

Referred to the House Committee on Natural Resources.

S 1272

Trade Review Act of 2025

Read twice and referred to the Committee on Finance. (Sponsor introductory remarks on measure: CR S2

HR 914

American CANS Act

Referred to the House Committee on Ways and Means.